{"result": "(\"entity\"<|>GLUCEMIA<|>EVENT<|>Glucemia refers to the presence of glucose in the blood, which is a critical factor in diagnosing diabetes and managing blood sugar levels.)\n##\n(\"entity\"<|>INSUFICIENCIA RENAL CRÓNICA<|>EVENT<|>Insuficiencia renal crónica is a medical condition characterized by the gradual loss of kidney function over time, which can complicate diabetes management.)\n##\n(\"entity\"<|>ANÁLISIS DE EMPRESA<|>EVENT<|>Análisis de empresa refers to the evaluation of a company's financial and operational performance, which may be relevant in the context of healthcare organizations managing diabetes care.)\n##\n(\"entity\"<|>TRATAMIENTO<|>EVENT<|>Tratamiento refers to the medical interventions and management strategies employed to control diabetes and its complications.)\n##\n(\"entity\"<|>CURVA CON 75 G DE GLUCOSA<|>EVENT<|>Curva con 75 g de glucosa is a diagnostic test used to assess how the body processes glucose, particularly in diagnosing gestational diabetes.)\n##\n(\"entity\"<|>DIABETES GESTACIONAL<|>EVENT<|>Diabetes gestacional is a type of diabetes that develops during pregnancy and typically resolves after childbirth, but requires careful management to avoid complications.)\n##\n(\"entity\"<|>CRITERIOS HAPO<|>EVENT<|>Criterios HAPO are the guidelines established by the HAPO study for diagnosing gestational diabetes based on specific glucose thresholds.)\n##\n(\"entity\"<|>SOG<|>EVENT<|>SOG (Sobrecarga Oral de Glucosa) is a test involving the administration of glucose to evaluate how the body handles sugar, particularly in diagnosing diabetes.)\n##\n(\"entity\"<|>METFORMINA<|>EVENT<|>Metformina is a medication commonly used to treat type 2 diabetes by improving insulin sensitivity and reducing glucose production in the liver.)\n##\n(\"entity\"<|>LINAGLIPTINA<|>EVENT<|>Linagliptina is a medication used to treat type 2 diabetes by increasing insulin release and decreasing glucagon levels.)\n##\n(\"entity\"<|>SULFONILUREAS<|>EVENT<|>Sulfonilureas are a class of medications used to treat type 2 diabetes by stimulating insulin secretion from the pancreas.)\n##\n(\"entity\"<|>ANOMALÍAS RENALES Y GENITALES<|>EVENT<|>Anomalías renales y genitales refer to congenital abnormalities affecting the kidneys and genital organs, which can be associated with certain types of diabetes.)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: vuelve desproporcionadamente\n                                                                                                                                                 mayor en el extremo superior del rango. En ausencia de una hiperglucemia inequívoca, el diagnóstico requiere dos resultados de\n       Las tres    categorías indicadas definen situaciones de prediabetes según la American Diabe-                                              prueba anormales de la misma muestra o en dos pruebas de muestras separadas.\n       tes Association.                                                                                                                          Adaptado de: American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019.\n                                                                                                                                                 Diabetes Care. 2019;42(Suppl. 1):S13-S28.\n       Referencias:\n       • American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care.     Referencias:\n         2019;42(Suppl. 1):S13-S28.                                                                                                              • American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care.\n                                                                                                                                                   2019;42(Suppl 1):S13-28. doi: 10.2337/dc19-S002. Review. PubMed PMID: 30559228.\n                                                                                                                                                 • American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019.\n                                                                                                                                                   Diabetes Care. 2019;42(Suppl 1):S90-102. doi: 10.2337/dc19-S009. Review. PubMed PMID: 30559235.\n    8  Varón     de 50     años, asintomático, que presenta                     en dos análisis de empresa\n       glucemias basales             de 132      y 130 mg/dl.        Tiene, además, 2. ¿Cuál es la actitud insuficiencia renal crónica\n       con filtrado glomerular              de 30 ml/min e IMC de 27 kg/m                                                     que             9  Según      los criterios HAPO            (Hyperglycemia and Pregnancy Outcomes) de diabetes\n       debe seguirse?                                                                                                                            gestacional, el valor            límite de la glucemia basal es:\n       A.  Se diagnostica de DM2 y se inicia tratamiento con medidas no farmacológicas.                                                          A.  110 mg/dl.\n       B.  Se pide curva con 75 g de glucemia para confirmar el diagnóstico.                                                                     B.  95 mg/dl.\n       C.  Se inicia tratamiento con linagliptina.                                                                                               C.  92 mg/dl.\n       D. Se repite la analítica en 2 años.                                                                                                      D.  105 mg/dl.\n\n\n\n82                                                                                                                                                                                                                                                                                       83\n---\n                                                                                                                                                                                                                               DIABETES                          2\n\n\n\n        COMENTARIO                                                                                                                        Tabla 2. Características clínicas de la diabetes tipo MODY\n        Para realizar el diagnóstico de diabetes gestacional según los criterios HAPO, se efectúa\n        una sobrecarga oral de glucosa (SOG) con 75 g de glucosa directament e y se mide a las                                               Tipo         Mutación            Características clínicas                               Tratamiento\n        0, 1 y 2 h. Valores iguales o superiores a 92, 180 y 153 mg/dl, respectivamente, en un solo                                                                           Defecto secretor progresivo. Riesgo de                 Responden a\n        punto ya son diagnósticos de diabetes gestacional.                                                                                  MODY 1       HFN-4α               complicaciones microvasculares                         sulfonilureas\n        Los criterios HAPO son más rigurosos, se recomendaron por primera vez en 2011 y muchos                                                                                Elevación de la glucemia en ayunas,                    No suele requerir\n        centros todavía no los aplican. Al aplicarlos se incrementa el número de mujeres afectadas                                          MODY 2       Glucocinasa           estable, no progresiva                                tratamiento. Insulina\n        de diabetes gestacional, de manera que el riesgo asciende desde el 5-6% con los criterios                                                                             Complicaciones microvasculares raras                   en embarazo\n        tradicionales al 15-20% con los criterios HAPO.                                                                                     MODY 3       HFN-1α               Riesgo de complicaciones microvasculares               Sensibles a\n        Referencias:                                                                                                                                                                                                                 sulfonilureas\n        • Metzger BE, Lowe LP, Dyer AR, et al.; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes.                                                                                                 Insulina/\n          N Engl J Med. 2008;358:1991-2002.                                                                                                 MODY 4       IPF-1                Agenesia pancreática en homocigotos                    antidiabéticos orales\n                                                                                                                                            MODY 5       HFN-1β               Anomalías renales y genitales. Riesgo de               Metformina. Insulina\n        ¿Cuál de las siguientes respuestas es cierta respecto a las diabetes de tipo MODY?                                                                                    complicaciones microvasculares\n    10\n        A. La diabetes MODY de tipo 2 (por alteración del gen de la glucocinasa) suele responder                                          Referencias:\n                                                                                                                                          • American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care.\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>AMERICAN DIABETES ASSOCIATION<|>ORGANIZATION<|>The American Diabetes Association is a professional organization that provides standards of medical care in diabetes and conducts research on diabetes management and treatment.)\n##\n(\"entity\"<|>DIABETES<|>EVENT<|>Diabetes is a chronic health condition that affects how the body processes blood sugar (glucose) and can lead to serious health complications if not managed properly.)\n##\n(\"entity\"<|>MODY<|>EVENT<|>MODY (Maturity Onset Diabetes of the Young) is a form of diabetes that is caused by a change in a single gene and is characterized by a defect in insulin secretion.)\n##\n(\"entity\"<|>HAPO<|>EVENT<|>HAPO (Hyperglycemia and Adverse Pregnancy Outcomes) is a study that established criteria for diagnosing gestational diabetes based on glucose levels during pregnancy.)\n##\n(\"relationship\"<|>AMERICAN DIABETES ASSOCIATION<|>DIABETES<|>The American Diabetes Association provides guidelines and standards for the classification and diagnosis of diabetes, including gestational diabetes.<|>8)\n##\n(\"relationship\"<|>DIABETES<|>MODY<|>MODY is a specific type of diabetes that falls under the broader category of diabetes, characterized by genetic factors affecting insulin secretion.<|>7)\n##\n(\"relationship\"<|>HAPO<|>DIABETES<|>The HAPO study provides diagnostic criteria for gestational diabetes, which is a specific type of diabetes that occurs during pregnancy.<|>8)\n##\n(\"relationship\"<|>AMERICAN DIABETES ASSOCIATION<|>HAPO<|>The American Diabetes Association references the HAPO study in its guidelines for the classification and diagnosis of diabetes, including gestational diabetes.<|>6)\n<|COMPLETE|>"}]}